Medical Incubator Japan K.K.
Venture capitalTokyo · Series A–Series B
Investment thesis
MIJ is a professional group specializing in healthcare investment. It invests in domestic and international startups developing first-in-class or best-in-class pharmaceuticals, spanning the latest technologies such as regenerative medicine and gene therapy through to small-molecule fields, as well as startups building devices and digital health services that bring innovation to the delivery of medical care. The firm combines global sourcing capabilities, evaluation expertise from healthcare business and investment professionals, and commercialization support intended to lead investments to success, aiming to bring hope to patients and returns to investors.
Source: firm website, verified Aug 3, 2026.
What they invest in
from 9 of 24 portfolio companiesHealthtech ×9Biotech ×8Medical Devices ×4Deep Tech ×3AI & Machine Learning ×1Digital Health ×1EdTech ×1
HQs:Japan×4United States×2United Kingdom×1
Investments · 24 tracked
founders shown can be your intro pathDermatology-focused R&D company using a proprietary nanoformulation technology to deliver drugs efficiently to hard-to-reach tissues like skin and nails.
Provides clinical information to physicians and healthcare professionals online and offers pharmaceutical companies effective drug-information delivery solutions (TSE Prime 2105).
Developing gene therapy adipocyte drugs carrying therapeutic protein genes for congenital enzyme/protein deficiency diseases.
Developing a pan-γδT cell engager that activates multiple γδT cell subsets to target antigens beyond the reach of conventional T cell engagers.
Cytospire Therapeutics develops multispecific antibodies and next-generation γδ T cell engagers designed to direct innate and adaptive immune effector cells as an alternative to CD3-based engagers.
BiotechHealthtech
DiscGenics develops an allogeneic, injectable disc progenitor cell therapy (IDCT/rebonuputemcel) for painful lumbar degenerative disc disease, currently advancing toward a Phase III clinical program.
BiotechHealthtechMedical DevicesSalt Lake City, US
Flagg Flanagan(CEO & Chairman)Bob Wynalek(COO & Board Member)
Heartseed develops cardiac regenerative medicine, creating heart muscle cells from iPS cells for transplantation to treat heart failure, with its lead pipeline HS-001 nearing clinical trials.
BiotechHealthtechMedical Devices
Keiichi Fukuda(代表取締役社長 (President & CEO))
Commercializing seed technology from Keio University for cardiac regenerative medicine; lead product is allogeneic iPS cell-derived cardiac spheroids (TSE Growth 219A).
Commercializing Keio University technology for cardiac regenerative medicine, with a lead allogeneic iPS-cell-derived cardiomyocyte spheroid product (TSE Growth 219A).
IgGenix is a clinical-stage biotechnology company focused on antibody discovery and development for allergies and immunological diseases.
AI & Machine LearningBiotechHealthtechSouth San Francisco, US
Kari Nadeau(Scientific Co-Founder)
ILC Therapeutics is a biotechnology company developing hybrid interferon therapeutics, including its Alfacyte product, based on an interferon platform.
BiotechDeep TechHealthtechMedical Devices
Owain Millington(CEO)
Biotech with a CRISPR-based therapeutic platform aiming to develop treatments for genetic diseases (TSE Growth 4883).
Developing innovative AAV-based gene therapies for intractable diseases including Parkinson's, ALS and Alzheimer's.
Develops, manufactures, and sells regenerative cell drugs for CNS disorders such as chronic stroke and traumatic brain injury (TSE Growth 4592).
Delivers clinical information to physicians and healthcare providers online and offers solutions for pharmaceutical companies' drug information activities (TSE Prime 2105).
Develops, manufactures and sells regenerative cell therapies for central nervous system disorders such as stroke and traumatic brain injury (TSE Growth 4592).
Developing gene therapy adipocyte-based products carrying therapeutic protein genes to treat inherited diseases caused by enzyme or functional protein deficiencies.
CellGenTech develops ex-vivo gene therapy products using gene-transduced human adipose cells (GMAC) to treat rare diseases such as familial LCAT deficiency, Fabry disease, and hemophilia.
BiotechDeep TechHealthtechChiba, JP
麻生雅是(代表取締役社長 (President & CEO))
Biotech with a CRISPR-based therapeutic platform aiming to develop treatments for genetic diseases (TSE Growth 4883).
A gene therapy company developing treatments for neurodegenerative diseases, with a pipeline of more than ten programs led by candidates for ALS and Parkinson's disease.
BiotechHealthtechMedical Devices
村松 慎一(Physician)
Modalis Therapeutics develops therapeutics using CRISPR gene-editing technology and provides its platform technology for drug development.
BiotechDeep TechHealthtechTokyo, JP
Haruhiko Morita(代表取締役CEO (President & CEO))
Frequently asked questions
- What stage does Medical Incubator Japan K.K. invest at?
- Medical Incubator Japan K.K. invests at the Series A, Series B stages.
- What sectors does Medical Incubator Japan K.K. focus on?
- Medical Incubator Japan K.K. focuses on Biotech, Digital Health, Healthtech, Medical Devices.
- Where is Medical Incubator Japan K.K. located?
- Medical Incubator Japan K.K. is headquartered in Tokyo, JP.
Similar investors
Amadeus Capital Partners is a UK-based deep tech venture capital firm founded in 1997 that invests from seed to growth stages across artificial intelligence, health, and sustainability-focused technologies.
B Capital Group is a global venture capital firm that backs founders from early to late stage, with dedicated stage-based funds and a portfolio spanning technology, healthcare, and energy and resilience sectors.
Breyer Capital is a venture capital firm that backs high-impact entrepreneurs, making strategic investments guided by founder passion and its network of experienced investors.
Capricorn Venture Partners is a European investment firm managing several thematic funds across growth capital, healthcare, and cleantech, as well as a combined private/quoted investment vehicle.
DCVC (Data Collective) is a venture capital firm that backs founders building companies which apply technology to major challenges across areas such as energy, biotech, agriculture, and machine learning.